Cale JM - Search Results

1

Is Exon Skipping a Viable Therapeutic Approach for Vascular Ehlers-Danlos Syndrome with Mutations in COL3A1 Exon 10 or 15?

Utama S, Cale JM, Mitrpant C, Fletcher S, Wilton SD, Aung-Htut MT. Utama S, et al. Among authors: cale jm. Int J Mol Sci. 2024 Aug 13;25(16):8816. doi: 10.3390/ijms25168816. Int J Mol Sci. 2024. PMID: 39201504 Free PMC article.

2

Proof-of-Concept: Antisense Oligonucleotide Mediated Skipping of Fibrillin-1 Exon 52.

Cale JM, Greer K, Fletcher S, Wilton SD. Cale JM, et al. Int J Mol Sci. 2021 Mar 27;22(7):3479. doi: 10.3390/ijms22073479. Int J Mol Sci. 2021. PMID: 33801742 Free PMC article.

3

Induced alternative splicing an opportunity to study PCSK9 protein isoforms at physiologically relevant concentrations.

Cale JM, Ham KA, Li D, McIntosh CS, Watts GF, Wilton SD, Aung-Htut MT. Cale JM, et al. Sci Rep. 2023 Nov 13;13(1):19725. doi: 10.1038/s41598-023-47005-y. Sci Rep. 2023. PMID: 37957262 Free PMC article.

4

A Patient Case of Malan Syndrome Involving 19p13.2 Deletion of NFIX with Longitudinal Follow-Up and Future Prospectives.

Makker S, Gagnon BR, Trew I, Mougios V, Hanna A, Cale JM, McIntosh CS. Makker S, et al. Among authors: cale jm. J Clin Med. 2024 Nov 1;13(21):6575. doi: 10.3390/jcm13216575. J Clin Med. 2024. PMID: 39518712 Free PMC article.

5

Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1.

Cale JM, Li SH, Warnock M, Su EJ, North PR, Sanders KL, Puscau MM, Emal CD, Lawrence DA. Cale JM, et al. J Biol Chem. 2010 Mar 12;285(11):7892-902. doi: 10.1074/jbc.M109.067967. Epub 2010 Jan 8. J Biol Chem. 2010. PMID: 20061381 Free PMC article.

6

Antenatal betamethasone depresses maternal and fetal aldosterone levels.

Kessel JM, Cale JM, Verbrick E, Parker CR Jr, Carlton DP, Bird IM. Kessel JM, et al. Among authors: cale jm. Reprod Sci. 2009 Jan;16(1):94-104. doi: 10.1177/1933719108324140. Reprod Sci. 2009. PMID: 18997118 Free PMC article.

7

Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.

Cale JM, Lawrence DA. Cale JM, et al. Curr Drug Targets. 2007 Sep;8(9):971-81. doi: 10.2174/138945007781662337. Curr Drug Targets. 2007. PMID: 17896949 Review.

8

The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin.

Stefansson S, Su EJ, Ishigami S, Cale JM, Gao Y, Gorlatova N, Lawrence DA. Stefansson S, et al. Among authors: cale jm. J Biol Chem. 2007 May 25;282(21):15679-89. doi: 10.1074/jbc.M702125200. Epub 2007 Apr 2. J Biol Chem. 2007. PMID: 17403662 Free article.

9

Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor.

Gorlatova NV, Cale JM, Elokdah H, Li D, Fan K, Warnock M, Crandall DL, Lawrence DA. Gorlatova NV, et al. Among authors: cale jm. J Biol Chem. 2007 Mar 23;282(12):9288-96. doi: 10.1074/jbc.M611642200. Epub 2007 Feb 2. J Biol Chem. 2007. PMID: 17276980 Free article.

10

Inhibition of MEK/ERK1/2 signalling alters endothelial nitric oxide synthase activity in an agonist-dependent manner.

Cale JM, Bird IM. Cale JM, et al. Biochem J. 2006 Sep 1;398(2):279-88. doi: 10.1042/BJ20060371. Biochem J. 2006. PMID: 16716148 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters